Published in World J Gastroenterol on June 28, 2014
Hepatitis B virus subgenotype A1: evolutionary relationships between Brazilian, African and Asian isolates. PLoS One (2014) 0.80
Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol (2016) 0.80
Aptamers in diagnostics and treatment of viral infections. Viruses (2015) 0.80
Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon. Virol J (2016) 0.78
Characterization of Acute and Chronic Hepatitis B Virus Genotypes in Canada. PLoS One (2015) 0.78
Molecular characterisation of hepatitis B virus in HIV-1 subtype C infected patients in Botswana. BMC Infect Dis (2015) 0.77
Induced immunity against hepatitis B virus. World J Hepatol (2015) 0.77
Three decades of hepatitis B control with vaccination. World J Hepatol (2015) 0.77
Broad Range of Hepatitis B Virus (HBV) Patterns, Dual Circulation of Quasi-Subgenotype A3 and HBV/E and Heterogeneous HBV Mutations in HIV-Positive Patients in Gabon. PLoS One (2016) 0.76
Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. Virology (2016) 0.75
HBV genotypic variability in Cuba. PLoS One (2015) 0.75
Reactivation of hepatitis B virus without core antibody. J Clin Microbiol (2015) 0.75
Inhibition of preS1-hepatocyte interaction by an array of recombinant human antibodies from naturally recovered individuals. Sci Rep (2016) 0.75
Oligonucleotide aptamers: potential novel molecules against viral hepatitis. Res Pharm Sci (2017) 0.75
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 6.12
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
The enigmatic X gene of hepatitis B virus. J Virol (2004) 2.98
Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol (2005) 2.95
Occult hepatitis B virus infection. J Hepatol (2006) 2.79
Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis (2007) 2.62
Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med (2006) 2.42
Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust (2009) 2.42
Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology (1983) 2.36
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Genetics of hepatocellular carcinoma. Semin Cancer Biol (2000) 2.30
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat (2002) 2.26
Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol (2009) 2.21
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol (2010) 2.20
Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol (1993) 2.16
Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J Virol (1995) 1.95
Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A (2003) 1.93
Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med (1987) 1.93
Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS (2002) 1.92
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology (2010) 1.92
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene (1997) 1.81
Hepatitis B virus genetic variability and evolution. Virus Res (2007) 1.80
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology (2006) 1.76
Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol (1993) 1.71
Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology (1999) 1.69
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2008) 1.65
Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene (1999) 1.63
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol (2008) 1.63
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat (1997) 1.58
Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest (1996) 1.48
Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol (1999) 1.46
Structural organization of the hepatitis B virus minichromosome. J Mol Biol (2001) 1.45
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (2014) 1.43
Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol (2001) 1.42
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis (2007) 1.40
In vitro model for the nuclear transport of the hepadnavirus genome. J Virol (1997) 1.38
Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol (1999) 1.34
Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol (2007) 1.32
The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Int J Oncol (1999) 1.31
Hepatitis B variant in Europe. Lancet (1988) 1.31
Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol (2012) 1.29
Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis (2006) 1.27
Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett (2013) 1.24
Mutations of the surface protein of hepatitis B virus. Antiviral Res (2003) 1.24
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol (1990) 1.24
Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. J Med Virol (2005) 1.24
Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion (2008) 1.20
The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology (2009) 1.18
Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS (2006) 1.18
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology (2000) 1.16
Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol (2002) 1.15
Molecular characteristics of occult hepatitis B virus from blood donors in southeast China. J Clin Microbiol (2009) 1.14
Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. J Gen Virol (1997) 1.14
Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J Hepatol (2003) 1.12
HBV-DNA in hemodialysis patients infected by HCV. Saudi J Kidney Dis Transpl (2009) 1.10
Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology (2006) 1.10
Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol (2008) 1.09
Frequency of hepatitis B virus 'a' determinant variants in unselected Spanish chronic carriers. J Med Virol (2006) 1.08
A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One (2012) 1.07
Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol (2007) 1.05
Hepatitis B Virus e Antigen Variants. Int J Med Sci (2005) 1.04
Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology (2006) 1.04
Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis (1997) 1.02
The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther (2008) 1.02
Presence of hepatitis B surface antigen mutant G145R DNA in the peripheral blood leukocytes of the family members of an asymptomatic carrier and evidence of its horizontal transmission. Virus Res (2002) 1.00
The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res (2012) 1.00
Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine (2001) 1.00
Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis (2008) 0.99
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment. Antimicrob Agents Chemother (2012) 0.99
Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (2003) 0.99
Intra-familial evidence of horizontal transmission of hepatitis B virus surface antigen mutant G145R. J Infect (2000) 0.99
Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol (2001) 0.98
Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis (2012) 0.98
The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol (2005) 0.97
Molecular characterization of occult hepatitis B cases in Greek blood donors. J Med Virol (2009) 0.97
Identification of hepatitis B surface antigen variants with alterations outside the "a" determinant in immunized Singapore infants. J Infect Dis (1999) 0.97
Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther (2010) 0.97
Molecular epidemiology of hepatitis B virus mutants. J Med Virol (1999) 0.97
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. Antiviral Res (2011) 0.97
Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab (2004) 0.95
Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol (2012) 0.95
The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine (1999) 0.94
Viral deletions among healthy young Chinese adults with occult hepatitis B virus infection. Virus Res (2011) 0.91
Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: A 3-year study of national surveillance of primary school students. Vaccine (2010) 0.91
Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients. Virology (2012) 0.90